PT - JOURNAL ARTICLE AU - Slavov, Svetoslav Nanev AU - Leister Patané, José Salvatore AU - Santos Bezerra, Rafael dos AU - Giovanetti, Marta AU - Fonseca, Vagner AU - Martins, Antonio Jorge AU - Viala, Vincent Louis AU - Rodrigues, Evandra Strazza AU - dos Santos, Elaine Vieira AU - dos Santos Barros, Claudia Renata AU - Marqueze, Elaine Cristina AU - Santos, Bibiana AU - Aburjaile, Flavia AU - Neto, Raul Machado AU - Moretti, Debora Botequio AU - Haddad, Ricardo AU - Calado, Rodrigo Tocantins AU - Paulo Kitajima, João AU - Freitas, Erika AU - Schlesinger, David AU - de Alcantara, Luiz Carlos Junior AU - Elias, Maria Carolina AU - Sampaio, Sandra Coccuzzo AU - Kashima, Simone AU - Covas, Dimas Tadeu TI - Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 lineage (20H/501Y.V2) in Brazil AID - 10.1101/2021.03.30.21254591 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.30.21254591 4099 - http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254591.short 4100 - http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254591.full AB - Sao Paulo State, the most populous area in Brazil, currently experiences a second wave of the COVID-19 pandemic which overwhelmed the healthcare system. Recently, due to the paucity of SARS-CoV-2 complete genome sequences, we established a Network for Pandemic Alert of Emerging SARS-CoV-2 Variants to rapidly understand the spread of SARS-CoV-2 and monitor in nearly real-time the circulating SARS-CoV-2 variants into the state. Through full genome analysis of 217 SARS-CoV-2 complete genome sequences obtained from the largest regional health departments we were able to identify the co-circulation of multiple SARS-CoV-2 lineages such as i) B.1.1 (0.92%), ii) B.1.1.1 (0.46%), iii) B.1.1.28 (25.34%), iv) B.1.1.7 (5.99%), v) B.1.566 (1.84%), vi) P.1 (64.05%), and P.2 (0.92%). Further our analysis allowed the detection, for the first time in Brazil of the South African variant of concern (VOC), the B.1.351 (501Y.V2) (0.46%). The identified lineage was characterized by the presence of the following mutations: ORF1ab: T265I, R724K, S1612L, K1655N, K3353R, SGF 3675_F3677del, P4715L, E5585D; Spike: D80A, D215G, L242_L244del, A262D, K417N, E484K, N501Y, D614G, A701V, C1247F; ORF3a: Q57H, S171L, E: P71L; ORF7b: Y10F, N: T205I; ORF14: L52F. Origin of the most recent common ancestor of this genomic variant was inferred to be between middle October to late December 2020. Analysis of generated sequences demonstrated the predominance of the P.1 lineage and allowed the early detection of the South African strain for the first time in Brazil. Our findings highlight the importance to increase active monitoring to ensure the rapid detection of new SARS-CoV-2 variants with a potential impact in pandemic control and vaccination strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Butantan Institute, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grant Number. 2020/10127; 2020/05367-3), Hemocentro Ribeirao Preto.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is approved by the Institutional Ethics Committe of the Faculty of Medicine of Ribeirao Preto, University of Sao PauloAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe obtained data is being deposited in the GISAID database together with this submission.